Nolvadex (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nolvadex, is a selective estrogen receptor modulator (SERM) presented as an oral tablet for oral use. It is employed in the treatment and prevention of estrogen receptor‑positive breast cancer and related hormone‑driven conditions in adult patients. It is indicated for both adjuvant and metastatic settings, as well as for risk reduction in high‑risk populations.

GNH USA supplies Nolvadex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Tamoxifen citrate (Nolvadex) targets estrogen‑dependent breast cancer pathways.

- Estrogen receptor‑positive breast cancer (adjuvant therapy): reduces recurrence risk after surgery. - Metastatic breast cancer: slows disease progression in advanced stages. - Prevention of breast cancer in high‑risk women: lowers incidence of new tumors. - Gynecomastia: treats hormone‑related breast tissue growth in men.

Tamoxifen citrate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Nausea: upset stomach often with mild vomiting. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins, potentially leading to swelling and pain. - Endometrial cancer: abnormal growth of uterine lining, requiring monitoring. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess thromboembolic risk: avoid use in patients with a history of clotting disorders. - Evaluate uterine health: consider periodic gynecologic assessment for endometrial changes. - Counsel on pregnancy: drug is contraindicated during pregnancy; effective contraception is required. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Tamoxifen citrate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect and bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise tamoxifen plasma concentrations. - Estrogen‑containing contraceptives: may reduce tamoxifen efficacy.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may affect tamoxifen metabolism. - Other anticoagulants: require INR monitoring. - CYP2D6 substrates: tamoxifen metabolism may be altered, adjust therapy as needed.